Search
Zorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
Proscillaridin
go.drugbank.com/drugs/DB13307ExperimentalStudies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations [A27193 … Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima).
Categories: Compounds used in a research, industrial, or household settingS-Hydroxycysteine
go.drugbank.com/drugs/DB01915ExperimentalIt targets the proteins subtilisin BPN', glutathione S-transferase A1, glutathione S-transferase p, myelin P2 protein, and complement c3. … S-hydroxycysteine is a solid. This compound belongs to the alpha amino acids and derivatives.
ATR-04
go.drugbank.com/drugs/DB26782InvestigationalATR-04 is a biologic drug. ATR-04 is under investigation in clinical trial NCT04731259 (Study to Evaluate the Safety of ATR-04).
Canfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. … Midecamycin is a naturally occurring 16-membered macrolide [A33072] that fits under the category of acetoxy-substituted macrolide antibiotics.
Synonyms: Espinomycin A, Medemycin A1Ecallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … It was discovered by phage display technology [A32017].
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalIn particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers … These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as
Icotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Cefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
Products: CEFADROXILO 250MG/5ML POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL